Japanese recommendation takes Sanwa's anagliptin closer to first market
This article was originally published in Scrip
Sanwa Kagaku Kenkyusho/Kowa's anagliptin (SK-0403) has moved a step closer to becoming the sixth DPP-4 inhibitor to be launched in Japan following a positive approval recommendation for the treatment of type 2 diabetes.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.